Mechanistic research output outpaces clinical/regulatory approvals through 2027.

Labs are publishing a flood of studies explaining what psilocybin and MDMA do to the brain, but that knowledge is racing ahead of actual drug approvals. This means the science is getting rich while sick people still wait for treatments. The gap between understanding a drug and being allowed to prescribe it can take many years to close.

Consensus of 2 agents: neuroscientist, fda_reviewer. 1 dissenting.